Clover Health launches drug development subsidiary

FierceHealthIT

Startup Medicare Advantage insurer Clover Health has launched a new drug development subsidiary called Clover Therapeutics.

From start to finish, drug development could benefit from cloud computing

Mobi Health News

From streamlining operations to fine-tuning optimal treatments, the technology makes a business case for pharma

Clover Health's new subsidiary will rely on members, machine learning to fuel drug development

Mobi Health News

Dubbed Clover Therapeutics, the unit's first project will be a partnership with Genentech targeting ocular diseases among senior populations

Enriching RWE with Novel Data Sets: How Medical Imaging Data Can Accelerate Drug Development

hea!thcare innovation - Clinical IT

Real-world evidence has the potential to be especially valuable in a number of healthcare use cases

AI Doesn’t Ask Why — But Physicians And Drug Developers Want To Know

Healthcare Guys

At long last, we seem to be on the threshold of departing the earliest phases of AI, defined by the always tedious “will AI replace doctors/drug developers/occupation X?” By DAVID SHAYWITZ MD.

Verily’s Deep-Learning Model Accurately Characterizes Proteins

MedTech Boston

Companies News deep learning drug development protein characterization verily deepmassVerily’s DeepMass, a deep-learning application for mass spectrometry, is highly accurate at predicting peptide mass spectra, according to a manuscript.

Ben-Gurion University introduces AI platform for monitoring and predicting ALS progression

Mobi Health News

Bioinformatics Market Size, Share and Demand Forecast to 2024

Healthcare Guys

They are mainly used in the medical sector, which is driven by the increasing use of bioinformatics for the drug development and discovery process Bioinformatics technologies are used in various pharmaceutical and biotechnology sectors.

BenevolentAI gets $115M to harness AI for new drug discovery

Mobi Health News

BenevolentAI, a UK company using artificial intelligence for drug development, has raised $115 million in new funding, mostly from undisclosed investors in the United States.

Cost of antibiotic-resistant infections in U.S. tops $2B per year

FierceHealthIT

The study’s authors urge policymakers to support the development of new strategies to prevent infections and to support innovative antibiotic drug development A new study finds that antibiotic resistance adds more than $1,000 to the cost of treatment for a single patient. Multiply that by the estimated number of antibiotic-resistant infections, and costs run well over $2 billion per year.

Moving the Needle with Real World Data: How Oncology is Leading the Way

GNS Healthcare

The thought of gathering massive amounts of data, from claims to EHR to molecular and making it easily accessible for drug development research once seemed impossible, as did getting at previously 'undruggable' pathways that defied the effects of even the most innovative drugs.

Health Consumers Are Now Amazon-Primed for Healthcare – HealthConsuming Explains, Part 2

Health Populi

As patients now assume the role of health consumer, they rationally expect retail-level experiences with greater first-dollar payment for health insurance, health care services and medical products like prescription drugs.

MedTech’s Role in Fighting the Opioid Epidemic

Duane Boise

Of the 50,000 drug overdose deaths that occurred in 2015, roughly 33,000 of them were caused by opioids. More forms of technology are being developed every day to treat patients suffering from chronic pain, and to remedy those that may be struggling with an opioid addiction.

#091: Francesca Wuttke on Digital Transformation, Startups and Corporate Relationships

Digital Health Today

Francesca is responsible for developing and executing an end-to-end company-wide digital transformation. And finally, she gave us a little insight into a new accelerator program that they’ve developed: the Digital Garden Powered by Almirall.

Digital Therapeutics: the keys to succeed!

Digital Health Today

The Digital Therapeutics Alliance developed a definition to differentiate DTx solutions from health and wellness apps. The ReSET Prescription Digital Therapeutic (PDT), developed in collaboration with Sandoz, treats patients with Substance Use Disorder (SUD).

Blockchain in Healthcare: A Vehicle Towards Digital Health 2.0?

The Digital Health Corner

Blockchain was first developed as a means of transaction for the digital currency Bitcoin. Blockchain technology’s potential impact on the life sciences industry (drug development, distribution and prescribing) is significant. It can impact the opioid crisis and improve tracking drugs in the supply chain. One can envision how blockchain might also stop drug counterfeiting thereby improving patient safety.

Lilly Acquires Rights to Nasal Glucagon

Insulin Nation

has acquired the worldwide rights to a nasal glucagon product being developed by Locemia Solutions, according to a recent press release. The acquisition is an attempt by Lilly to bolster its troubled drug pipeline.

Blockchain: Its Future in Healthcare is Happening Now

Phoenix Health Systems

For physicians, this would enable customized individual treatment plans co-developed by a patient’s various caregivers, based on full histories, patient genetics, lifecycle and environment. Interoperability. Blockchain.

Leveraging T2D Drugs to improve T1D Therapy

Insulin Nation

In his studies, Type 1 diabetic patients have significantly benefited when their daily insulin regimen is supplemented with drugs developed to treat Type 2 diabetes. This was the first research ( release ) on using this Type 2 approved drug for T1D treatment and there were larger confirmatory studies ( release ) in 2016 and 2018. The study will supplement insulin therapy with these two drugs designed to treat Type 2 Diabetes or with semaglutide alone. “

Novartis CEO Is Going All in With Some Big Bets on R&D

Lloyd Price

In an interview with the Wall Street Journal, Narasimhan pointed to some of the investments the company has made into the cutting-edge areas of drug development, such as gene therapy and radiopharmaceuticals.

Donald Trump and Diabetes Policy: What We Know Right Now

Insulin Nation

Within a bullet point about Obamacare is this sentence: “Reforms will also include cutting the red tape at the FDA: there are over 4,000 drugs awaiting approval, and we especially want to speed the approval of life-saving medications.”.

FemTech: The rise of Female Health innovation

Lloyd Price

CVC’s recent acquisition of the women’s health division of the Israeli drug developer Teva for $800m created a company dedicated to contraception, fertility, menopause and osteoporosis. Silicon Valley Bank, Zinc.vc

Lilly Acquires Rights to Nasal Glucagon

Insulin Nation

has acquired the worldwide rights to a nasal glucagon product being developed by Locemia Solutions, according to a recent press release. The acquisition is an attempt by Lilly to bolster its troubled drug pipeline.

How the 21st Century Cures Act Will Change Diabetes Care

Insulin Nation

This legislation boosts funding to the National Institutes of Health and establishes an innovation grant fund to “accelerate the discovery, development, and delivery” of new treatments and therapies. She also said the bill opened the door to easy off-label use of FDA-cleared drugs. “I

What is Metformin?

Insulin Nation

A drug prescription can come with a lot of questions. With our “Know Your Drugs” series, we provide you with a snapshot of the different diabetes drugs on the market, and links to additional information.

Genomics Startup Human Longevity’s Valuation Falls 80% from $1.6 Billion down to $310M

Lloyd Price

But key facets of its business didn’t develop as planned, say people familiar with the company. It had hoped to sell analytics to pharmaceutical companies as they increasingly incorporated genetic sequencing into drug development, these people say. Human Longevity Inc.

BCG Vaccine Shows Promising Signals of T1D Efficacy

Insulin Nation

We found in human and mouse research that defects in white blood cells causing disease had a signaling pathway that we could drug. We looked for generic drugs that stimulate TNF. The Hygiene Hypothesis was developed in the UK in the 1960s.

Join us at the Global Clinical Trials Connect 2018, 25-26 April, London

mHealth Insight

“The Global Clinical Trials Connect 2018 conference focuses on introducing pioneer technology, developing better patient engagement and collaborating strategies in clinical trials. Aji Barot, Business Development Director, HealthUnlocked.

Lilly Acquires Rights to Nasal Glucagon

Insulin Nation

has acquired the worldwide rights to a nasal glucagon product being developed by Locemia Solutions, according to a recent press release. The acquisition is an attempt by Lilly to bolster its troubled drug pipeline.

New Blockchain ledger will let US residents sell personal Healthcare data

Lloyd Price

Most people don't know it but there is a multi-billion dollar industry that collects healthcare information, strips it of basic personal identifiers such as name, address and Social Security Number, and then sells it off to researchers, drug developers, marketers and others.

FDA Gives Diabetes Treatments Low Priority

Insulin Nation

DiMasi, PhD, who analyzes the economics of health care at the Tufts University Center for the Study of Drug Development. We’ve seen very large trials and lengthening clinical development times, which would suggest larger than average development costs,” DiMasi said.

Artificial Intelligence in Healthcare: What We Know so Far

Perficient

It will also help facilitate drug development. A recent article by Fortune describes how future healthcare practitioners hope to have screened enough people to uncover new biomarkers that can help predict cancer before it develops. The healthcare industry is changing every day; from best practices to technological advancements. The industry is seeing exponential growth in regards to virtual reality, 3D printing, and artificial intelligence.

Path to Better Clinical Trials for T1D Delay/Prevention

Insulin Nation

The Critical Path Institute (C-Path) is a catalyst in the development of new approaches including biomarkers and modeling and analysis tools to support clinical trial design and clinical outcome assessments.